Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $1.2 million.

  • Contineum Therapeutics' Other Accumulated Expenses fell 12.54% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 12.54%. This contributed to the annual value of $3.2 million for FY2024, which is 103.82% up from last year.
  • Contineum Therapeutics' Other Accumulated Expenses amounted to $1.2 million in Q3 2025, which was down 30.49% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Other Accumulated Expenses peaked at $3.2 million during Q4 2024, and registered a low of $973,000 during Q2 2024.
  • For the 3-year period, Contineum Therapeutics' Other Accumulated Expenses averaged around $1.8 million, with its median value being $1.6 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 103.82% in 2024, then decreased by 12.54% in 2025.
  • Contineum Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.5 million in 2023, then skyrocketed by 103.82% to $3.2 million in 2024, then declined by 12.54% to $1.2 million in 2025.
  • Its Other Accumulated Expenses was $1.2 million in Q3 2025, compared to $1.7 million in Q2 2025 and $2.5 million in Q1 2025.